It’s an exciting time to be at ACADIA, and participating in the company’s transformation from a development-stage company to an integrated biopharmaceutical company is a significant opportunity. In my previous job, I experienced the company’s first launch and many more over the years. At ACADIA, part of my role is to make sure we have the resources we need to hire talented people with the right experience. The company is growing and for me this is a chance to be involved in building our organization for future success.
Senior Director, Biosciences
I joined ACADIA at its inception, when it was a small start-up organization. Our mission then was to use modern molecular techniques to make drugs with greatly improved efficacy, safety and tolerability compared to available drugs to better serve patients suffering from neuropsychiatric disorders. I was involved in the research that led to the discovery of NUPLAZID™, our proprietary, selective 5-HT2A serotonin receptor inverse agonist that is being developed as a novel treatment for Parkinson’s disease psychosis. We have undergone the ups and downs many biotech companies experience, but we have made tremendous progress and remained focused on our original goals. I am excited about the future and I look forward to the next phase of ACADIA’s development.